Cadrenal Therapeutics Reports $2.5 Million Net Loss in Q1 2026, Seeks Additional Capital

Cadrenal Therapeutics, Inc. reported a net loss of $2.5 million for the first quarter of 2026, a significant improvement compared to a net loss of $3.8 million during the same period in 2025. The company’s total operating expenses decreased by 36% to $2.5 million, down from $3.9 million in the prior year. This reduction was primarily driven by lower general and administrative expenses, which fell by 23% to $1.7 million, and a 54% decrease in research and development expenses, which totaled $0.8 million. The decrease in operating expenses reflects the company's ongoing efforts to manage costs while advancing its clinical programs.

In terms of financial position, Cadrenal's total assets decreased to $2.9 million as of March 31, 2026, down from $4.3 million at the end of 2025. The decline in cash and cash equivalents was notable, dropping to $2.3 million from $4.0 million. The company’s accumulated deficit increased to $41.5 million, reflecting its ongoing investment in research and development. Current liabilities also decreased to $1.1 million from $1.6 million, indicating improved management of short-term obligations.

Strategically, Cadrenal has made significant advancements in its product pipeline, particularly with its lead candidate, CAD-1005, which is being developed for the treatment of heparin-induced thrombocytopenia (HIT). The company recently completed an End-of-Phase 2 meeting with the FDA, receiving guidance on the design of a pivotal Phase 3 trial expected to begin soon. Additionally, Cadrenal has expanded its portfolio through the acquisition of assets from eXIthera Pharmaceuticals and Veralox Therapeutics, which include promising compounds for thrombotic conditions.

Operationally, Cadrenal's cash flow from financing activities for the first quarter of 2026 was approximately $1.3 million, primarily from sales under its at-the-market (ATM) facility. The company sold 168,690 shares at an average price of $8.10 per share. However, the company anticipates that its existing cash resources will not be sufficient to fund operations for the next 12 months, prompting plans to seek additional capital through various means, including equity offerings and strategic partnerships. The company’s ability to continue operations is contingent on securing this funding, raising substantial doubt about its ability to continue as a going concern.